We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+37.76%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.9B
AUM Growth
+$644M
Cap. Flow
-$263M
Cap. Flow %
-5.37%
Top 10 Hldgs %
40.38%
Holding
132
New
23
Increased
22
Reduced
35
Closed
25

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$41.7M
2
BMY icon
Bristol-Myers Squibb
BMY
+$37.3M
3
ELV icon
Elevance Health
ELV
+$33.5M
4
HELP
Cybin Inc
HELP
+$24.7M
5
BRKR icon
Bruker
BRKR
+$23.5M

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$125M
2
RNAM
Avidity Biosciences
RNAM
+$65.8M
3
EXAS
Exact Sciences
EXAS
+$51.6M
4
AXSM icon
Axsome Therapeutics
AXSM
+$38.9M
5
SIBN icon
SI-BONE Inc
SIBN
+$38M

Sector Composition

Rank Sector Weight
1 Healthcare 99.3%
2 Miscellaneous 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
126
CALL
TG Therapeutics
TGTX
$8.26B
– –
-100,000
Closed -$3.61M
VSTM icon
127
Verastem
VSTM
$654M
– –
-887,561
Closed -$7.84M
XERS icon
128
Xeris Biopharma Holdings
XERS
$1.55B
– –
-80,420
Closed -$655K
BTSG icon
129
CALL
BrightSpring Health Services
BTSG
$11.7B
– –
-150,000
Closed -$4.43M
DHAI
130
DELISTED
DIH Holdings US
DHAI
– –
-76,600
Closed -$358K
2 3 4 5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q4 2025 Portfolio in Review

As of Q4 2025, OrbiMed held 132 positions worth $4.9B, up 15% from $4.26B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed withdrew a net $263M in Q4 2025, closing 25 positions and reducing 35 holdings. Its most notable exit was SI-BONE Inc, an estimated $38M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Pfizer worth $41.2M.

  • OrbiMed's largest Q4 2025 buy was Pfizer: 1,652,900 shares worth $41.2M.
  • OrbiMed added most to RAPT Therapeutics in Q4 2025, an estimated $17.3M increase.
  • OrbiMed's biggest Q4 2025 reduction was Terns Pharmaceuticals, cutting an estimated $125M.
  • OrbiMed fully exited SI-BONE Inc in Q4 2025, selling an estimated $38M.
  • OrbiMed's ten largest holdings make up 40% of its $4.9B portfolio in Q4 2025.
  • OrbiMed opened 23 new positions and closed 25 in Q4 2025.
  • OrbiMed's portfolio value rose 15% quarter-over-quarter to $4.9B.

Based on OrbiMed's 13F filing for Q4 2025, filed 17 Feb 2026.